摘要
随着PLATO研究的公布,替格瑞洛因其良好的药理学特性及显著的临床获益被欧美指南推荐为一线或首选的抗血小板药物治疗急性冠状动脉综合征,但是替格瑞洛增加了出血风险.而出血发生率的增高与患者不良临床预后相关.本文对替格瑞洛的药动学、药效学、安全性和耐受性等方面进行综述.
As the publication of PLATO study,ticagrelor has been recommended as the preferred antiplatelet drug for acute coronary syndrome by European and American guidelines because of the excellent pharmacological properties and significant clinical benefits.But ticagrelor increases the risk of bleeding.Many clinical trials has demonstrated that bleeding is strongly associated with poor prognosis.This review discussed the pharmacokinetic and pharmacodynamics properties of ticagrelor,as well as the safety and tolerability.
出处
《中国医药》
2016年第4期607-610,共4页
China Medicine
基金
北京市卫生和计划生育委员会国家临床重点专科建设项目（2013-2014）
北京市医院管理局重点医学专业发展计划（ZYLX201303）
首都卫生发展科研专项项目（首发2011-2006-04）
北京市保健科研课题（京13-11、京13-12）
